ArticleOncology letters2026
Clinicopathological role of microRNA-205, microRNA-223 and microRNA-590 in vulvar cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvar cancer is a rare malignancy whose development involves environmental, immunologic, genetic and viral factors, including high-risk HPV infection. MicroRNAs (miRNAs/miRs) regulate key oncogenic pathways and may serve as biomarkers in gynecological cancers. However, limited data are available on the role of miR-205, miR-223 and miR-590 in vulvar carcinoma. The present study thus assessed their expression and clinical relevance. A total of 38 women with vulvar carcinoma were included in the study. miRNA expression was quantified using reverse transcription-quantitative PCR from formalin-fixed paraffin-embedded surgical specimens. Among the enrolled patients, 25 had both tumor tissue and matched non-malignant vulvar tissue available for analysis, enabling paired comparisons and fold-change calculations, whereas 13 patients contributed tumor tissue only due to insufficient RNA yield from the matched non-malignant specimen. Statistical analyses included paired t-tests and Kaplan-Meier survival analysis. Clinicopathological features were evaluated using International Federation of Gynecology and Obstetrics (FIGO) staging and histological grading. The results revealed that miR-205 expression was higher in patients with advanced disease, with a significant difference observed between FIGO I-III and FIGO IV tumors. miR-223 expression exhibited a tendency toward an association with poorer tumor differentiation, suggesting its potential as an unfavorable prognostic indicator. miR-590 expression was associated with tumor grade, with higher levels detected in well-differentiated lesions; additionally, the absence of miR-590 expression was linked to a lower likelihood of malignancy, supporting its diagnostic value. A reduced expression of miR-223 was independently associated with an improved overall survival (log-rank, P=0.013). No significant associations between miR-205 or miR-590 and overall survival were identified. On the whole, the present study demonstrated that miR-205, miR-223 and miR-590 expression patterns are associated with the tumor stage, grading and survival outcomes of patients with vulvar cancer. These miRNAs may thus serve as diagnostic or prognostic biomarkers, with miR-223 exhibiting the strongest prognostic significance and miR-590 demonstrating diagnostic specificity. Due to the rarity of vulvar cancer, larger multicenter studies and international datasets are required to validate these findings and to further elucidate the biological roles of miRNAs in this malignancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.